Amlong 5 vs Cilacar 10 — Calcium Channel Blockers, Pedal Edema & Generic Savings

Side-by-Side Formulation & Pharmacological Comparison Matrix

1. Executive Summary & Clinical Verdict

Amlong 5 (Amlodipine 5mg by Micro Labs) and Cilacar 10 (Cilnidipine 10mg by J.B. Chemicals) represent two generations of dihydropyridine calcium channel blockers (CCBs) widely prescribed for essential hypertension in India. While both effectively reduce systemic vascular resistance and blood pressure, their channel-selectivity profile leads to profound clinical differences in side effect profiles:

Amlodipine is a selective L-type calcium channel blocker that dilates precapillary resistance arterioles without dilating postcapillary venules. This hydraulic mismatch causes elevated intracapillary hydrostatic pressure and fluid extravasation, resulting in dependent pedal edema (ankle swelling) in 10% to 15% of long-term users, alongside reflex sympathetic tachycardia.

Cilnidipine is a modern dual L-type and N-type calcium channel blocker. By blocking N-type calcium channels located on sympathetic nerve terminals, Cilnidipine suppresses sympathetic norepinephrine outflow, preventing reflex tachycardia. Crucially, it induces balanced vasodilation of both precapillary arterioles and postcapillary venules, preserving microvascular hydrostatic pressure and virtually eliminating pedal edema. Furthermore, Cilnidipine dilates both afferent and efferent renal glomerular arterioles, significantly reducing intraglomerular pressure and urinary protein excretion in hypertensive diabetic nephropathy. Under the PMBJP Jan Aushadhi formulary, generic Cilnidipine 10mg costs ₹22.00 for 10 tablets and Amlodipine 5mg costs ₹8.00 for 10 tablets, providing an 87% direct cost saving.

2. Cellular Mechanisms: L-Type vs. Dual L/N-Type Channel Blockade

Vascular tone is regulated by calcium influx through voltage-dependent calcium channels situated in vascular smooth muscle and adrenergic nerve terminals:

L-Type Calcium Channels (Amlodipine Target): L-type (long-lasting) calcium channels are predominantly distributed on arterial smooth muscle cells. When action potentials depolarize the cell membrane, L-type channels open, allowing extracellular calcium to enter the cytosol. Calcium binds to calmodulin, activating myosin light chain kinase (MLCK), which phosphorylates myosin heads and triggers arterial vasoconstriction. Amlodipine binds allosterically to the dihydropyridine receptor on the alpha-1 subunit of L-type channels, stabilizing the inactive closed conformation and provoking arterial relaxation. However, L-type channels are sparse on postcapillary venules; consequently, Amlodipine causes isolated precapillary dilation.

N-Type Calcium Channels (Cilnidipine Added Advantage): N-type (neuronal) calcium channels are localized on peripheral sympathetic postganglionic nerve terminals and the autonomic endings innervating the kidney and heart. When sympathetic stimulation occurs, calcium influx through N-type channels triggers exocytosis of norepinephrine vesicles. Cilnidipine possesses high affinity for both L-type and N-type channels. By blocking N-type channels, Cilnidipine attenuates sympathetic nerve firing and inhibits excess norepinephrine discharge. This confers three distinct advantages: (1) Absence of reflex heart rate surges; (2) Dilation of postcapillary venules to eliminate pedal edema; (3) Efferent glomerular arteriolar dilation to protect the kidneys.

3. Hemodynamics of Dependent Pedal Edema

Understanding why 10% to 15% of patients prescribed Amlodipine discontinue therapy due to distressing ankle and foot swelling requires analyzing Starling forces in the microcirculation:

Under normal physiological conditions, precapillary arteriolar tone and postcapillary venular resistance remain balanced, maintaining an intracapillary hydrostatic pressure of approximately 25 to 30 mmHg at the arterial end and 10 to 15 mmHg at the venular end.

When Amlodipine induces potent, selective precapillary arteriolar vasodilation while postcapillary venules remain undilated, the high systemic arterial pressure is transmitted directly into the delicate capillary bed. Intracapillary hydrostatic pressure rises abruptly, exceeding the counterbalancing oncotic pressure of plasma albumin. Fluid filters out into the interstitial tissue of dependent extremities (the feet, ankles, and pretibial region), presenting as pitting pedal edema.

Cilnidipine completely bypasses this complication. Because Cilnidipine inhibits sympathetic tone via N-channel blockade, it relaxes both the precapillary sphincter and the postcapillary venule equally. Capillary inflow and outflow expand in tandem, preventing intracapillary pressure spikes and maintaining interstitial fluid balance.

4. Renal Hemodynamics & Nephroprotection in Diabetes

In patients with hypertension and comorbid diabetes mellitus, intraglomerular hypertension accelerates glomerulosclerosis, leading to microalbuminuria and end-stage renal disease:

Amlodipine dilates the afferent glomerular arteriole without dilating the efferent arteriole, which can transmit systemic blood pressure into the glomerulus and maintain elevated glomerular filtration pressure.

Cilnidipine blocks N-type calcium channels heavily expressed on renal sympathetic nerves that regulate efferent arteriolar tone. Consequently, Cilnidipine dilates both afferent and efferent glomerular arterioles. This reduces intraglomerular capillary pressure, decreases podocyte mechanical stress, and significantly lowers urinary albumin excretion (proteinuria), making Cilacar 10 the clinically superior CCB for diabetic hypertensive patients.

5. Pharmacokinetics, Bioavailability & Chronotherapy

Amlodipine Besylate has an exceptionally long elimination half-life of 35 to 50 hours, resulting in slow, smooth onset of action and steady-state plasma concentrations after 7 to 8 days of daily dosing. Absolute oral bioavailability is ~64% to 90%. Because of its prolonged half-life, a single missed dose of Amlodipine rarely precipitates acute rebound hypertension.

Cilnidipine exhibits an elimination half-life of 5 to 10 hours in plasma; however, its lipophilic nature and high tissue partition coefficient allow it to remain tightly bound to vascular dihydropyridine receptors for 24 hours, providing true once-daily blood pressure reduction.

Chronotherapy: For patients exhibiting 'non-dipper' status (failure of blood pressure to dip by 10% to 20% during sleep), taking Cilnidipine or Amlodipine at bedtime improves nocturnal pressure control and reduces early morning cardiovascular events.

6. Adverse Reaction Profile & Clinical Triage

Amlodipine Adverse Effects: Dependent pedal edema is the most prevalent complaint (occurring in 10% to 15% of patients taking 10 mg and ~5% taking 5 mg). Headaches, cutaneous flushing, and reflex palpitations are reported in 2% to 5% of users. Gingival hyperplasia (gum enlargement) is a recognized long-term adverse effect.

Cilnidipine Adverse Effects: Incidence of pedal edema is exceptionally low (<1.5%). Occasional mild headache, dizziness, nausea, or abdominal discomfort can occur during the initial 1 to 2 weeks of titration.

Clinical Triage: When a patient on Amlong 5 develops ankle swelling, clinicians should switch the patient directly to Cilacar 10 rather than adding a loop diuretic (e.g., Furosemide), which is ineffective for CCB-induced capillary edema and can cause electrolyte depletion.

7. Drug Interactions & CYP3A4 Pathway

Both Amlodipine and Cilnidipine undergo Phase I oxidative metabolism primarily via Cytochrome P450 3A4 (CYP3A4):

Inhibitors of CYP3A4 (Ketoconazole, Itraconazole, Erythromycin, Diltiazem, Grapefruit juice) decrease the clearance of both CCBs, leading to elevated plasma concentrations, pronounced vasodilation, and symptomatic hypotension.

Simvastatin Interaction: Amlodipine increases Simvastatin exposure by 77%; patients co-prescribed Amlodipine should not exceed a Simvastatin dose of 20 mg daily (or should be switched to Rosuvastatin or Atorvastatin).

Inducers of CYP3A4 (Rifampicin, Carbamazepine, Phenytoin) accelerate CCB elimination, reducing antihypertensive efficacy.

8. CDSCO Regulatory Schedule & Jan Aushadhi Economics

Both medications are listed under Schedule H of the Drugs and Cosmetics Rules. Branded Amlong 5 (Micro Labs) retails at ₹68.00 for 15 tablets (₹4.53/tablet), and Cilacar 10 (J.B. Chemicals) retails at ₹175.00 for 15 tablets (₹11.67/tablet). Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, generic Amlodipine 5mg Tablets IP cost ₹8.00 for 10 tablets (₹0.80/tablet), and generic Cilnidipine 10mg Tablets IP cost ₹22.00 for 10 tablets (₹2.20/tablet). For a patient requiring lifelong antihypertensive therapy, switching from branded Cilacar 10 to Jan Aushadhi generic Cilnidipine reduces annual medication bills from ~₹4,259.00 down to ~₹803.00—delivering an 81% direct cost reduction.

Frequently Asked Clinical Questions • Evidence-Based Answers